Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer (vol 12, pg 74, 2022)P. A. Janne,C. Baik,W. C. Su,M. Johnson,H. Hayashi, M. NishioCANCER DISCOVERY（2022）引用 1|浏览9暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
